EVO301, a Long-Acting Candidate, Shows Early Promise in Atopic Dermatitis
Long-acting investigational therapy EVO301 showed promise in a proof-of-concept atopic dermatitis study, an early signal that extended-interval dosing may advance into larger controlled trials.